Co-Diagnostics (HAM:C970) Total Equity: €13.88 Mil (As of Mar. 2026)


HAM:C970 Co-Diagnostics Inc HAM:C970
60 GF Score
Price €5.55
GF Value €3.88
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Total Equity?

Co-Diagnostics HAM:C970 60 Total Equity is €13.88 Mil as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 60/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review.

Co-Diagnostics's total equity for the quarter that ended in Mar. 2026 was €13.88 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Co-Diagnostics Total Equity Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Total Equity Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.01 108.11 78.88 51.45 17.62

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.33 35.67 33.93 17.62 13.88
HAM:C970
60GF Score
Co-Diagnostics Inc HAM:C970
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Co-Diagnostics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=21.131-3.513
=17.62

Co-Diagnostics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=18.597-4.72
=13.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €13.88 Mil mean?
Co-Diagnostics (HAM:C970) has a Total Equity of €13.88 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Co-Diagnostics and its competitors.
Is Co-Diagnostics' Total Equity too high?
Co-Diagnostics' current Total Equity is €13.88 Mil. Overall, Co-Diagnostics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Total Equity compare to ALRTF and SINT?
Co-Diagnostics' Total Equity of €13.88 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Co-Diagnostics and its competitors. Co-Diagnostics's current Total Equity is €13.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Total Equity of €13.88 Mil. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current Total Equity is €13.88 Mil. Co-Diagnostics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Total Equity is €13.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.

Key valuation signals for HAM:C970:

  • Total Equity: €13.88 Mil
  • GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
60GF Score

Get the complete analysis for HAM:C970

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€3.88
GF Value